Saad Z. Usmani, MD, discusses the combination of carfilzomib and filanesib as a treatment for multiple myeloma.
Saad Z. Usmani, MD, director, Plasma Cells Disorder Program, Levine Cancer Institute/Carolinas Healthcare System, discusses the combination of carfilzomib and filanesib as a treatment for multiple myeloma. Usmani said a recent phase II study showcased a response rate of 14% in the carfilzomib-only arm, while a response rate of 35% was seen in the arm with patients receiving a combination of carfilzomib and filanesib.
Usmani said the regimen was efficacious, though the main question still persisting post study is how much dosing of carfilzomib should be included in an upcoming phase III study.
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
Creating Solutions for a 'Continual State of Transition' in Cancer Care
April 15th 2024In a Peers & Perspectives in Oncology feature article, we focus on the importance of the transition-of-care process for patients with cancer as they move from the inpatient to outpatient setting, as well as between lines of therapy with comments from Marc J. Braunstein, MD, PhD, and Michael Shusterman, MD.
Read More